Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    51 - 75 out of 236Page size: 25
    Sort by: 1st author
    1. Published

      Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

      Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

      Research output: Contribution to journal › Journal article › peer-review

    2. Published

      A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials

      Deacon, Carolyn F., Feb 2018, In: Diabetes, Obesity and Metabolism. 20, p. 34-46 13 p.

      Research output: Contribution to journal › Review › peer-review

    3. Published

      Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

      Deacon, Carolyn F., Feb 2018, In: Peptides. 100, p. 150-157 8 p.

      Research output: Contribution to journal › Journal article › peer-review

    4. Published

      Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

      Research output: Contribution to journal › Journal article › peer-review

    5. Published

      GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

      Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

      Research output: Contribution to journal › Journal article › peer-review

    6. Published

      GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

      Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

      Research output: Contribution to journal › Journal article › peer-review

    7. Published

      Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

      Deacon, Carolyn F., 2008, In: Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.

      Research output: Contribution to journal › Journal article › peer-review

    8. Published

      Therapeutic strategies based on glucagon-like peptide 1.

      Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.

      Research output: Contribution to journal › Journal article › peer-review

    9. Published

      Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

      Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

      Research output: Contribution to journal › Journal article › peer-review

    10. Published

      Potential of liraglutide in the treatment of patients with type 2 diabetes

      Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

      Research output: Contribution to journal › Journal article › peer-review

    11. Published

      MK-431 (Merck).

      Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

      Research output: Contribution to journal › Journal article › peer-review

    12. Published

      Immunoassays for the incretin hormones GIP and GLP-1

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

      Research output: Contribution to journal › Journal article › peer-review

    13. Published

      Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

      Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

      Research output: Contribution to journal › Journal article › peer-review

    14. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

      Research output: Contribution to journal › Journal article › peer-review

    15. Published

      Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review

      Deacon, Carolyn F., Jan 2011, In: Diabetes, Obesity and Metabolism. 13, 1, p. 7-18 12 p.

      Research output: Contribution to journal › Review › peer-review

    16. Published

      Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

      Deacon, Carolyn F., 2019, In: Frontiers in Endocrinology. 10, 14 p., 80.

      Research output: Contribution to journal › Review › peer-review

    17. Published

      Potential cardiovascular effects of incretin-based therapies

      Deacon, Carolyn F. & Marx, N., 2012, In: Expert Review of Cardiovascular Therapy. 10, p. 337-351

      Research output: Contribution to journal › Review › peer-review

    18. Published

      Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

      Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, 4, p. 333-347 15 p.

      Research output: Contribution to journal › Review › peer-review

    19. Published

      A comparative review of DPP-4 inhibitors and sulphonylureas

      Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, p. 333-347

      Research output: Contribution to journal › Journal article › peer-review

    20. Published

      Circulation and degradation of GIP and GLP-1

      Deacon, Carolyn F., 2004, In: Hormone and Metabolic Research. 36, p. 761-765

      Research output: Contribution to journal › Journal article › peer-review

    21. Published

      Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

      Deacon, Carolyn F., Mannucci, E. & Ahren, B., 2012, In: Diabetes, Obesity and Metabolism Online. 14, 8, p. 762-767

      Research output: Contribution to journal › Review › peer-review

    22. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-140 8 p.

      Research output: Contribution to journal › Review › peer-review

    23. Published

      DPP-4 inhibitors

      Deacon, Carolyn F., 2016, Handbook of incretin therapies in type 2 diabetes. Gough, S. (ed.). Switzerland: Springer, p. 45-60

      Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

    24. Published

      Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

      Deacon, Carolyn F., 2020, In: Nature Reviews Endocrinology. 16, 11, p. 642-653

      Research output: Contribution to journal › Review › peer-review

    25. Published

      A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomised controlled trials

      Deacon, Carolyn F., 2018, In: Diabetes, Obesity and Metabolism. 20, Suppl. 1, p. 34-46

      Research output: Contribution to journal › Review › peer-review

    Previous 1 2 3 4 5 6 7 8 ...10 Next

    ID: 9220